A Prospective Cohort Study on Warfarin Personalized Medication

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

272 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-01

Study Completion Date

2023-12-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Analyze the impact of the degree of blood vessel aging on the anticoagulant effect and bleeding risk of warfarin. Evaluating the possibility of using the degree of blood vessel aging to guide individualized use of the anticoagulant drug warfarin.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Study of Warfarin Maintenance Dose in Chinese Patients

NCT01855737

Atrial Fibrillation Heart Valve Disease Pulmonary Artery Embolism

UNKNOWN

Dabigatran Versus Warfarin With NVAF Who Undergo PCI

NCT03536611

Atrial Fibrillation Coronary Artery Disease

UNKNOWN PHASE4

Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients

NCT01610141

Atrial Fibrillation Deep Vein Thrombosis Pulmonary Embolism +1 more

UNKNOWN PHASE4

The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement.

NCT02710747

Heart Valve Disease Older Than 18-years-old Without Any Liver or Kidney Diseases

UNKNOWN PHASE4

Direct Oral Anticoagulants and Venous Thromboembolism

NCT02833987

Venous Thromboembolism Major Bleed

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Warfarin Sodium Causing Adverse Effects in Therapeutic Use

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients taking warfarin with vascular aging group

Intervention Type OTHER

Patients taking warfarin with normal vascular group

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 65 years and older, taking warfarin, with or without premature vascular aging, regardless of gender.

* Patients who have not concurrently or intermittently used anticoagulant drugs, including antiplatelet drugs, heparin, low molecular weight heparin, and non-vitamin K-dependent oral anticoagulants, such as dabigatran and apixaban.

* Signing an informed consent form before blood sample collection.

Exclusion Criteria

* Patients who are allergic to warfarin or lactose.

* Patients who are receiving immunosuppressive agents or low molecular weight heparin anticoagulants.

* Patients with bleeding tendencies, blood disorders with platelet counts \> 400 × 10\^9 /L or \< 100 × 10\^9 /L, hemoglobin \> 169 or \< 100 g/L.

* History of peptic ulcer disease.

* Malignant tumors, severe multi-organ dysfunction or failure such as heart, liver, and kidney.

* Neurological disorders such as epilepsy.

Minimum Eligible Age

65 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No